...
首页> 外文期刊>Acta biomaterialia >Biomimetic modification of poly(vinyl alcohol): Encouraging endothelialization and preventing thrombosis with antiplatelet monotherapy
【24h】

Biomimetic modification of poly(vinyl alcohol): Encouraging endothelialization and preventing thrombosis with antiplatelet monotherapy

机译:聚(乙烯醇)的仿生改性:促进内皮化和预防抗血小板单疗法的血栓形成

获取原文
获取原文并翻译 | 示例

摘要

Poly(vinyl alcohol) (PVA) has shown promise as a biomaterial for cardiovascular application. However, its antifouling properties prevent in vivo endothelialization. This work examined the endothelialization and thrombogenicity of modified PVA with different concentrations of proteins and adhesion peptides: collagen, laminin, fibronectin, GFPGER, YIGSR, and cRGD. Material surface properties were quantified, and the endothelialization potential was determined with human endothelial colony forming cells. Additionally, platelet attachment was assessed in vitro with human platelet rich plasma, and promising samples were tested in an ex vivo shunt model. This well-established arteriovenous shunt model was used with and without clinically-relevant antiplatelet therapies, specifically acetylsalicylic acid (ASA) with and without clopidogrel to examine the minimum necessary treatment to prevent thrombosis. Collagen, laminin, and GFPGER biomolecules increased endothelialization, with GFPGER showing the greatest effect at the lowest concentrations. GFPGER-PVA tubes tested under whole blood did exhibit an increase in platelet (but not fibrin) attachment compared to plain PVA and clinical controls. However, application of ASA monotherapy reduced the thrombogenicity of GFPGER-PVA below the clinical control with the ASA. This work is significant in developing cardiovascular biomaterials increasing endothelialization potential while reducing bleeding side effects by using an antiplatelet monotherapy, typical of clinical patients.
机译:聚(乙烯醇)(PVA)已显示是作为心血管应用的生物材料的承诺。然而,其防污性能防止体内内皮化。该工作检测了具有不同浓度的蛋白质和粘附肽的改性PVA的内皮化和血栓形成性:胶原蛋白,层粘连蛋白,纤连蛋白,GFPGER,YIGSR和CRGD。量化材料表面性质,用人内皮菌落形成细胞测定内皮化电位。另外,在体外评估血小板附着的体外富血浆,并在前体内分流模型中测试有希望的样品。这种成熟的动静脉分流模型用于和没有临床相关的抗血小板疗法,特别是乙酰胱氨酸(ASA),具有和无氯吡格雷,以检查预防血栓形成的最小必要性治疗。胶原蛋白,层内蛋白和GFPGER生物分子增加了内皮化,GFPGER显示了最低浓度的最大效果。与普通PVA和临床对照相比,在全血下测试的GFPGER-PVA管确实表现出血小板(但不是纤维蛋白)附着的增加。然而,ASA单药治疗的应用降低了GFPGER-PVA的血栓形成性,低于临床对照与ASA。这种作品在开发心血管生物材料方面的显着增加内皮大学,同时通过使用抗血小板单疗法,典型的临床患者减少出血副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号